Expression changes of cytotoxicity and apoptosis genes in HTLV-1-associated myelopathy/tropical spastic paraparesis patients from the perspective of system virology

References

1. Gallo RC. The discovery of the first human retrovirus: HTLV-1 and HTLV-2. Retrovirology 2005; 2:17 [View Article][PubMed]
   [Google Scholar]
2. Keikha M, Marcondes Fonseca LA, Casseb J. The relevance of HTLV-1-associated myelopathy/tropical spastic paraparesis in Iran: a review study. Rev Clin Med 2019; 6:60–65
   [Google Scholar]
3. Shoeibi A, Rafatpanah H, Azarpazhooh A, Mokhber N, Hedayati-Moghaddam MR et al. Clinical features of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in northeast Iran. Acta Neurol Belg 2013; 113:427–433 [View Article][PubMed]
   [Google Scholar]
4. Ratner L. Molecular biology of human T cell leukemia virus. Semin Diagn Pathol 2019; 16: [View Article]
   [Google Scholar]
5. Mohammadi A, Fazeli B, Poursina Z, Tehranian F, Vakili V et al. Htlv-1-Infected asymptomatic carriers compared to HAM/TSP patients over-express the apoptosis-and cytotoxicity-related molecules. Med Microbiol Immunol 20191-0
   [Google Scholar]
6. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002; 2:401409 [View Article]
   [Google Scholar]
7. Benedict CA, Norris PS, Ware CF. To kill or be killed: viral evasion of apoptosis. Nat Immunol 2002; 3:10131018 [View Article]
   [Google Scholar]
8. Fuzii HT, da Silva Dias GA, de Barros RJS, Falcão LFM, Quaresma JAS. Immunopathogenesis of HTLV-1-assoaciated myelopathy/tropical spastic paraparesis (HAM/TSP). Life Sci 2014; 104:9–14 [View Article][PubMed]
   [Google Scholar]
9. Mozhgani S-H, Zarei-Ghobadi M, Teymoori-Rad M, Mokhtari-Azad T, Mirzaie M et al. Human T-lymphotropic virus 1 (HTLV-1) pathogenesis: a systems virology study. J Cell Biochem 2018; 119:3968–3979 [View Article][PubMed]
   [Google Scholar]
10. Tattermusch S, Skinner JA, Chaussabel D, Banchereau J, Berry MP et al. Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy. PLoS Pathog 2012; 8:e1002480 [View Article][PubMed]
    [Google Scholar]
11. Johnson JM, Harrod R, Franchini G. Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus type-1 (HTLV-1). Int J Exp Pathol 2001; 82:135–147 [View Article][PubMed]
    [Google Scholar]
12. Cook LB, Elemans M, Rowan AG, Asquith B. Htlv-1: persistence and pathogenesis. Virology 2013; 435:131–140 [View Article][PubMed]
    [Google Scholar]
13. Mozhgani SH, Piran M, Zarei-Ghobadi M, Jafari M, Mokhtari-Azad T et al. An insight to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) pathogenesis evidence from high-throughput data integration and meta-analysis. bioRxiv 2019; 754697:
    [Google Scholar]
14. Iwasaki Y. Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP). J Neurol Sci 1990; 96:103–123 [View Article][PubMed]
    [Google Scholar]
15. Tisato V, Gonelli A, Voltan R, Secchiero P, Zauli G. Clinical perspectives of TRAIL: insights into central nervous system disorders. Cell Mol Life Sci 2016; 73:2017–2027 [View Article][PubMed]
    [Google Scholar]
16. Mc Guire C, Beyaert R, van Loo G. Death receptor signalling in central nervous system inflammation and demyelination. Trends Neurosci 2011; 34:619–628 [View Article][PubMed]
    [Google Scholar]
17. Araya N, Sato T, Ando H, Tomaru U, Yoshida M et al. Htlv-1 induces a Th1-like state in CD4+CCR4+ T cells. J Clin Invest 2014; 124:3431–3442 [View Article][PubMed]
    [Google Scholar]
18. Yamano Y, Araya N, Sato T, Utsunomiya A, Azakami K et al. Abnormally high levels of virus-infected IFN-γ+CCR4+CD4+CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS One 2009; 4:e6517 [View Article][PubMed]
    [Google Scholar]
19. Kuroda Y, Matsui M. Cerebrospinal fluid interferon-gamma is increased in HTLV-I-associated myelopathy. J Neuroimmunol 1993; 42:223–226 [View Article][PubMed]
    [Google Scholar]
20. Montanheiro PA, Penalva de Oliveira AC, Smid J, Fukumori LMI, Olah I et al. The elevated interferon gamma production is an important immunological marker in HAM/TSP pathogenesis. Scand J Immunol 2009; 70:403–407 [View Article][PubMed]
    [Google Scholar]
21. Enose-Akahata Y, Vellucci A, Jacobson S. Role of HTLV-1 Tax and HBZ in the pathogenesis of HAM/TSP. Front Microbiol 2017; 8:2563 [View Article][PubMed]
    [Google Scholar]
22. Nagai M, Yamano Y, Brennan MB, Mora CA, Jacobson S. Increased HTLV-I proviral load and preferential expansion of HTLV-I tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. Ann Neurol 2001; 50:807–812 [View Article][PubMed]
    [Google Scholar]
23. Karimi M, Mohammadi H, Hemmatzadeh M, Mohammadi A, Rafatpanah H et al. Role of the HTLV-1 viral factors in the induction of apoptosis. Biomed Pharmacother 2017; 85:334–347 [View Article][PubMed]
    [Google Scholar]
24. Kannagi M, Ohashi T, Hanabuchi S, Kato H, Koya Y et al. Immunological aspects of rat models of HTLV type 1-infected T lymphoproliferative disease. AIDS Res Hum Retroviruses 2000; 16:1737–1740 [View Article][PubMed]
    [Google Scholar]
25. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the Bcl-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15:4963 [View Article][PubMed]
    [Google Scholar]
26. Zhang M, Mathews Griner LA, Ju W, Duveau DY, Guha R et al. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Proc Natl Acad Sci U S A 2015; 112:12480–12485 [View Article][PubMed]
    [Google Scholar]
27. Khouri R, Silva-Santos G, Dierckx T, Menezes SM, Decanine D et al. A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and apoptosis in healthy controls and adult T-cell leukemia patients. Oncoimmunology 2018; 7:e1426423 [View Article][PubMed]
    [Google Scholar]
28. Moles R, Bai XT, Chaib-Mezrag H, Nicot C. WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells. J Hematol Oncol 2016; 9:121 [View Article][PubMed][PubMed]
    [Google Scholar]
29. Mohammadi A, Fazeli B, Taheri M, Sahebkar A, Poursina Z et al. Modulatory effects of curcumin on apoptosis and cytotoxicity-related molecules in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. Biomed Pharmacother 2017; 85:457–462 [View Article][PubMed]
    [Google Scholar]
30. Kawatsuki A, Yasunaga J-I, Mitobe Y, Green PL, Matsuoka M. HTLV-1 bZIP factor protein targets the Rb/E2F-1 pathway to promote proliferation and apoptosis of primary CD4(+) T cells. Oncogene 2016; 35:45094517 [View Article][PubMed]
    [Google Scholar]
31. Hutchison T, Malu A, Yapindi L, Bergeson R, Peck K et al. The TP53-Induced Glycolysis and Apoptosis Regulator mediates cooperation between HTLV-1 p30II and the retroviral oncoproteins Tax and HBZ and is highly expressed in an in vivo xenograft model of HTLV-1-induced lymphoma. Virology 2018; 520:39–58 [View Article][PubMed]
    [Google Scholar]
32. Mühleisen A, Giaisi M, Köhler R, Krammer PH, Li-Weber M. Tax contributes apoptosis resistance to HTLV-1-infected T cells via suppression of Bid and Bim expression. Cell Death Dis 2014; 5:e1575 [View Article][PubMed]
    [Google Scholar]
33. Mukai R, Ohshima T. Dual effects of HTLV-1 bZIP factor in suppression of interferon regulatory factor 1. Biochem Biophys Res Commun 2011; 409:328–332 [View Article][PubMed]
    [Google Scholar]